drugset / Trial / NCT02334163

The Effects of Nitazoxanide in Hepatic Encephalopathy

NCT02334163

RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluating the efficacy and safety of nitazoxanide in comparison to standard treatment in patients with grade II-III hepatic encephalopathy (HE). Also, Evaluating the effect of administering nitazoxanide on the improvement of patient's quality of life.

Timeline

Start
2014-12
Primary completion
2015-02
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metronidazole Small molecule 250 mg
Subject Nitazoxanide Other / unclassified 500 mg
Comparator rifaximine Unknown 400 mg
Background Lactulose Other / unclassified Oral